Maximilian Wiendl

Erlangen, BY 91054, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Discrepant Phenotyping of Monocytes Based on CX3CR1 and CCR2 Using Fluorescent Reporters and Antibodies.

Discrepant Phenotyping of Monocytes Based on CX3CR1 and CCR2 Using Fluorescent Reporters and Antibodies.

Journal: Cells

Published: April 05, 2024

Etrolizumab-s fails to control E-Cadherin-dependent co-stimulation of highly activated cytotoxic T cells.

Etrolizumab-s fails to control E-Cadherin-dependent co-stimulation of highly activated cytotoxic T cells.

Journal: Nature communications

Published: March 22, 2023

Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing.

Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing.

Journal: Clinical and translational medicine

Published: December 19, 2022

Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.

Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.

Journal: Journal of Crohn's & colitis

Published: December 16, 2022

Nr4a1-dependent non-classical monocytes are important for macrophage-mediated wound healing in the large intestine.

Nr4a1-dependent non-classical monocytes are important for macrophage-mediated wound healing in the large intestine.

Journal: Frontiers in immunology

Published: September 09, 2022

Manual cell selection in single cell transcriptomics using scSELpy supports the analysis of immune cell subsets.

Manual cell selection in single cell transcriptomics using scSELpy supports the analysis of immune cell subsets.

Journal: Frontiers in immunology

Published: August 24, 2022

Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells.

Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells.

Journal: Inflammatory bowel diseases

Published: January 17, 2022

Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab.

Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab.

Journal: Gut

Published: April 10, 2021

Targeting Immune Cell Trafficking - Insights From Research Models and Implications for Future IBD Therapy.

Targeting Immune Cell Trafficking - Insights From Research Models and Implications for Future IBD Therapy.

Journal: Frontiers in immunology

Published: January 20, 2021

Intestinal Mucosal Wound Healing and Barrier Integrity in IBD-Crosstalk and Trafficking of Cellular Players.

Intestinal Mucosal Wound Healing and Barrier Integrity in IBD-Crosstalk and Trafficking of Cellular Players.

Journal: Frontiers in medicine

Published: December 19, 2020

Circulating Adaptive Immune Cells Expressing the Gut Homing Marker α4β7 Integrin Are Decreased in COVID-19.

Circulating Adaptive Immune Cells Expressing the Gut Homing Marker α4β7 Integrin Are Decreased in COVID-19.

Journal: Frontiers in immunology

Published: December 08, 2020

The JAK1/3 inhibitor tofacitinib suppresses T cell homing and activation in chronic intestinal inflammation.

The JAK1/3 inhibitor tofacitinib suppresses T cell homing and activation in chronic intestinal inflammation.

Journal: Journal of Crohn's & colitis

Published: June 28, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026